strengths container graph

Our Core Strengths Create the Foundation for Diversified, Durable and Transformative Growth

As a global medical technology innovator leading the way in women’s health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in The Science of Sure®, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION CORE BUSINESS PRODUCTS KEY GROWTH-DRIVING PRODUCTS

DIAGNOSTIC
SOLUTIONS

diagnostic Solutions white pie
panther
aptima ThinPrep

Panther® • Aptima® STI Assays •

ThinPrep® Pap Test and Cytology Instruments
aptima boxes

Aptima BV and CV/TV Assays

  • Molecular nucleic acid amplification tests.
  • Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.
  • Tens of millions of women suffer from these infections annually.
Breast Test

Breast Cancer Index™

  • Used to predict which breast cancer patients are likely to benefit from an extension of adjuvant anti-estrogen therapy.
  • The only test of its kind recognized by key medical societies.
  • Reimbursed by Medicare and key insurance providers.
Aptima Quant

Aptima Quant Virology Assays

  • Industry-leading accuracy of assays for HIV-1, HCV and HBV.
  • Life-changing testing for viruses affecting patients worldwide, including millions in sub-Saharan Africa, whom we support throught Hologic's Global Access Initiative.
Panther Fusion

Panther Fusion® and Panther Scalable Solutions

  • Provide access to Hologic's full menu of molecular diagnostic tests.
  • Allow labs to expand existing molecular testing capabilities without a major staffing investment.
  • Increase flexibility, capacity and walkaway time.
Digital Citology

Digital Cytology

  • First CE-marked digital cytology platform to combine an artificial intelligence (AI) algorithm with advanced volumetric imaging technology.
  • The world's most comprehensive cervical cancer screening portfolio — from sample collection to digital diagnosis.
  • Helps healthcare providers by supplying critical information needed for earlier detection and better treatment decisions.
Novodiag

Novodiag®

  • Fully automated molecular diagnostic platform ideal for use in "near-patient" healthcare settings.
  • Precise results available in about an hour.
  • Quiet, stackable design that's easy to use.

BREAST & SKELETAL
HEALTH SOLUTIONS

breast and SKELETAL white pie
3Dimensions
LOcalizer Affirm Breast System
Trident System

3Dimensions® • Affirm ® Breast Biopsy Systems •

Trident® Specimen Radiography System •

LOCalizer™ Wire-free Guidance System
Brevera

Brevera®

  • Breast biopsy system provides real-time imaging and analysis of specimens, potentially saving an average of 12 minutes per procedure.
  • Intuitive user interface and automated specimen collection.
  • Streamlined, accurate procedures reduce a patient's time under breast compression.
Genius AI

Genius AI™

  • Supports radiologists in improving accuracy and consistency of breast cancer detection.
  • Designed to maximize effectiveness of digital breast tomosynthesis (3D mammography).
  • Software is fully integrated on 3Dimensions systems.
Interventional Needles

Interventional Needles

  • Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems.
  • Provide ease of use with world-class accuracy, consistency and efficiency.
Tissue Markers

Tissue Markers

  • Serve a fast-expanding market segment of products for breast-conserving surgery.
  • Minimally invasive innovations that enable structural stabilization and enhance imaging and radiation treatment.

GYN SURGICAL
SOLUTIONS

GYN SURGICAL white pie
Novasure Image MyoSure

NovaSure® • MyoSure®
Fluent

Fluent®

  • Fluid management system for hysteroscopies.
  • Provides simplified set-up and operation.
  • Advanced technology offers streamlined workflow, greater ease-of-use, more consistent fluid management — all contributing to increased clinical confidence.
Acessa

Acessa®

  • Minimally invasive, laparoscopic radiofrequency ablation system.
  • Treats nearly all types of fibroids utilizing specialized heat energy.
  • Widely expanding recognition of underlying technology's efficacy by insurers and medical societies.
CollSeal

CoolSeal® Portfolio

  • Gold standard of efficacy for advanced, bipolar vessel sealing.
  • Versatile applications for both pediatric and gynecologic procedures.
  • Devices cut and dissect with precision in tight spaces and with less thermal spread.
Omni Hysteroscope

Omni® Hysteroscope

  • Scope with long length to facilitate easier access and enable both diagnosis and treatment with a single instrument.
  • Provides a clear view of the cervical canal and uterine cavity.
  • Three sheaths with small diameters enhance patient comfort.

Enabling healthier lives everywhere, every day.

Growing Performance, Growing Impact and Growing Recognition

Revenue Highlights 3Q23

Revenue ($M) 3Q23 Reported ∆
Vs 3Q22 		CC ∆ Vs 3Q22
Diagnostics $439.7 (21.5%) (21.3%)
Organic Diagnostics ex. COVID-192 $374.2 11.5% 11.8%
Organic Molecular Diag. ex. COVID-19 $247.4 12.6% 12.9%
Breast Health $360.3 27.4% 27.5%
GYN Surgical $157.3 13.9% 14.5%
Skeletal Health $27.1 24.9% 25.0%
Total Revenue $984.4 (1.8%) (1.6%)
Organic Revenue2 $973.7 (2.0%) (1.8%)
Organic ex. COVID-193 $918.9 18.1% 18.4%
US Revenue $750.1 2.1% -
Intl Revenue $234.3 (12.6%) (11.6%)

Financial Overview 3Q23

Non-GAAP
In Millions ex. EPS 		3Q23 ∆ vs. 3Q22
Revenue ($M) $984.4 (1.8%)
Organic Revenue2 $973.7 (2.0%)
Organic ex. COVID-193 $918.9 18.1%
Gross Margin 60.8% (250) bps
Operating Expenses $313.9 0.9%
Operating Margin 28.9% (340) bps
Net Margin 23.5% (60) bps
Diluted EPS $0.93 (2.1%)
EBITDA $311.9 (10.5%)

Financial Guidance for Fourth Quarter Fiscal 2023

Non-GAAP 4Q23 Reported vs. 4Q22 CC vs. 4Q22 Organic4 vs. 4Q22
Revenue ($M) $910 - $950 (4.5%) to (0.3%) (5.2%) to (1.0%) (5.1%) to (0.9%)
Non-GAAP EPS $0.80 - $0.87 (2.4%) to 6.1%
GAAP EPS $0.63 - $0.70 34.0% to 48.9%

Financial Guidance for Full Year Fiscal 2023

Non-GAAP FY23 Reported vs. FY22 CC vs. FY22 Organic4 vs. FY22
Revenue ($M) $3,995 - $4,035 (17.8%) to (17.0%) (17.1%) to (16.2%) (17.3%) to (16.5%)
Non-GAAP EPS $3.87 - $3.94 (35.7%) to (34.6%)
GAAP EPS $2.10 - $2.17 (59.1%) to (57.7%)
Capital Deployment Priorities
  • Expect strong cash flow in our fiscal fourth quarter and full year 2023
  • Business development priorities:
- Tuck-in acquisitions - Attractive to revenue, EPS growth rates - Attractive ROIC - Leverage existing strengths and capabilities

Financial Results

Net Debt & Leverage Ratio1

Revenue & CC Growth Rates

2022 Divisional Revenue by Geography

Non-GAAP EPS & Growth Rates

Adjusted Operating Cash Flow5

ROIC

  1. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  2. Organic revenue excludes divested Blood business.
  3. Total organic revenue excluding COVID-19.
  4. Organic revenue on a constant currency basis. Excludes the divested Blood business.
  5. Operating cash flow adjusted for one-time tax and litigation items.

PART-00000 REV 000 © 2023 Hologic Inc. All rights reserved. Hologic and The Science of Sure are trademarks of Hologic Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, Acessa, Affirm, Aptima, Breast Cancer Index, Brevera, CoolSeal, Dimensions, Fluent, LOCalizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, ThinPrep. All other trademarks, registered trademarks and product names are the property of their respective owners.

Purpose-Driven Company

Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.

Purpose Drive Graph
Global Health:
  • Hologic Global Women’s Health Index represents the views of 94% of the world’s women and girls aged 15 or older.
  • Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
  • Philanthropic donations aid charitable groups focused on women’s health, STEM education and social equity.
Global Reach:

Locations in 36+ countries with direct staff and a market presence in more than 100 countries.

Global Headquarters:

Marlborough, Massachusetts, US.